Compare Incyte Corporation (INCY) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Zillow Group Inc Class C — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Zillow Group Inc Class C trades at $32.02 (market cap $7.54B). The key difference: Incyte Corporation is far larger — about 3.1× Zillow Group Inc Class C's market cap, and Incyte Corporation is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| INCY | Z | |
|---|---|---|
Market Cap | $23.11B | $7.54B |
Sector | Health | Media |
52-Week High | $118.52 | $90.35 |
52-Week Low | $67.38 | $29.41 |
Enterprise Value | $19.13B | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Zillow Group (Z) trades at $33.03, down 2.58% today, amid ongoing class action lawsuits alleging securities fraud between February 2025 and May 2026. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, yet high P/E of 135.72 reflects premium valuation. Analyst consensus is divided with 46% Buy, 50% Hold, and a $57.67 price target implying significant upside from current levels.
The outlook is clouded by legal risks and volatile cash flows, but improving profitability and analyst targets suggest long-term potential if the company navigates litigation successfully. Key risks include lawsuit outcomes and competitive pressures in real estate tech, while institutional sentiment remains cautiously optimistic given the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
